SCHEMBL4995015

SCHEMBL4995015

COCCN(C)c1ccc(NC=C2C(=O)Nc3ccc(F)cc32)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 9/20 0.40
PRKAA1 Q13131 5/20 0.40
PRKAA2 P54646 4/20 0.40
KDR P35968 4/20 0.40
PDGFRB P09619 3/20 0.40
CCNE1 P24864 2/20 0.40
CDK2 P24941 2/20 0.40
FGFR1 P11362 2/20 0.40
CCNE2 O96020 1/20 0.40
NTRK1 P04629 5/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NTRK3 Q16288 3/20 0.38
PLK4 O00444 2/20 0.38
DCLK1 O15075 2/20 0.38
PDPK1 O15530 2/20 0.38
DAPK3 O43293 2/20 0.38
ROCK2 O75116 2/20 0.38
RPS6KA5 O75582 2/20 0.38
RPS6KA4 O75676 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4995009 1.00 FLT3 (0.40) FLT3PRKAA1PRKAA2KDRPDGFRB
SCHEMBL4993967 0.93 TGM2 (0.43) FLT3PRKAA1PRKAA2KDRPDGFRB
SCHEMBL4993973 0.93 TGM2 (0.43) FLT3PRKAA1PRKAA2KDRPDGFRB
SCHEMBL4996772 0.90 SMN1; SMN2 (0.44) KDRPDGFRBMEN1KMT2ARET
SCHEMBL4996775 0.90 SMN1; SMN2 (0.44) KDRPDGFRBMEN1KMT2ARET
SCHEMBL4994944 0.88 FLT3 (0.40) FLT3PRKAA1PRKAA2KDRPDGFRB
SCHEMBL4994940 0.88 FLT3 (0.40) FLT3PRKAA1PRKAA2KDRPDGFRB
SCHEMBL4990880 0.87 CCNE1 (0.42) FLT3PRKAA1PRKAA2KDRPDGFRB
SCHEMBL4990887 0.87 CCNE1 (0.42) FLT3PRKAA1PRKAA2KDRPDGFRB
SCHEMBL4995764 0.83 EGFR (0.38) FLT3KDRPDGFRBNTRK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
EP-1430048-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-06-23 EP disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed
WO-2003027102-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PRKAA1 402/4885PRKAA2 427/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PRKAA1 402/4885PRKAA2 427/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PRKAA1 402/4885PRKAA2 427/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PRKAA1 402/4885PRKAA2 427/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PRKAA1 402/4885PRKAA2 427/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 FLT3 255/4885PRKAA1 402/4885PRKAA2 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.